|
1
|
Ali AY, Farrand L, Kim JY, Byun S, Suh JY,
Lee HJ and Tsang BK: Molecular determinants of ovarian cancer
chemoresistance: New insights into an old conundrum. Ann N Y Acad
Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Behbakht K, Sill MW, Darcy KM, Rubin SC,
Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK and Alpaugh
RK: Phase II trial of the mTOR inhibitor, temsirolimus and
evaluation of circulating tumor cells and tumor biomarkers in
persistent and recurrent epithelial ovarian and primary peritoneal
malignancies: A Gynecologic Oncology Group study. Gynecol Oncol.
123:19–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott CL, Meier W,
Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in
patients with platinum-sensitive relapsed serous ovarian cancer: A
preplanned retrospective analysis of outcomes by BRCA status in a
randomised phase 2 trial. Lancet Oncol. 15:852–861. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matulonis UA, Berlin S, Ivy P, Tyburski K,
Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra
SA, et al: Cediranib, an oral inhibitor of vascular endothelial
growth factor receptor kinases, is an active drug in recurrent
epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin
Oncol. 27:5601–5606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lan F, Nottke AC and Shi Y: Mechanisms
involved in the regulation of histone lysine demethylases. Curr
Opin Cell Biol. 20:316–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Metzger E, Wissmann M, Yin N, Müller JM,
Schneider R, Peters AH, Günther T, Buettner R and Schüle R: LSD1
demethylates repressive histone marks to promote
androgen-receptor-dependent transcription. Nature. 437:436–439.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lim S, Janzer A, Becker A, Zimmer A,
Schüle R, Buettner R and Kirfel J: Lysine-specific demethylase 1
(LSD1) is highly expressed in ER-negative breast cancers and a
biomarker predicting aggressive biology. Carcinogenesis.
31:512–520. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu CY, Hsieh CY, Huang KE, Chang C and
Kang HY: Cryptotanshinone down-regulates androgen receptor
signaling by modulating lysine-specific demethylase 1 function. Int
J Cancer. 131:1423–1434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayami S, Kelly JD, Cho HS, Yoshimatsu M,
Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al:
Overexpression of LSD1 contributes to human carcinogenesis through
chromatin regulation in various cancers. Int J Cancer. 128:574–586.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schulte JH, Lim S, Schramm A, Friedrichs
N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L,
Kuhfittig-Kulle S, et al: Lysine-specific demethylase 1 is strongly
expressed in poorly differentiated neuroblastoma: Implications for
therapy. Cancer Res. 69:2065–2071. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang Y, Greene E, Stewart Murray T,
Goodwin AC, Baylin SB, Woster PM and Casero RA Jr: Inhibition of
lysine-specific demethylase 1 by polyamine analogues results in
reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA.
104:8023–8028. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng YC, Duan YC, Ma JL, Xu RM, Zi X, Lv
WL, Wang MM, Ye XW, Zhu S, Mobley D, et al:
Triazole-dithiocarbamate based selective lysine specific
demethylase 1 (LSD1) inactivators inhibit gastric cancer cell
growth, invasion, and migration. J Med Chem. 56:8543–8560. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harris WJ, Huang X, Lynch JT, Spencer GJ,
Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, et
al: The histone demethylase KDM1A sustains the oncogenic potential
of MLL-AF9 leukemia stem cells. Cancer Cell. 21:473–487. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schenk T, Chen WC, Göllner S, Howell L,
Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, et
al: Inhibition of the LSD1 (KDM1A) demethylase reactivates the
all-trans-retinoic acid differentiation pathway in acute myeloid
leukemia. Nat Med. 18:605–611. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen C, Ge J, Lu Q, Ping G, Yang C and
Fang X: Expression of Lysine-specific demethylase 1 in human
epithelial ovarian cancer. J Ovarian Res. 8:282015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Konovalov S and Garcia-Bassets I: Analysis
of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human
ovarian tumors and the effects of chemical LSD1 inhibitors in
ovarian cancer cell lines. J Ovarian Res. 6:752013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shao G, Wang J, Li Y, Liu X, Xie X, Wan X,
Yan M, Jin J, Lin Q, Zhu H, et al: Lysine-specific demethylase 1
mediates epidermal growth factor signaling to promote cell
migration in ovarian cancer cells. Sci Rep. 5:153442015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shao GB, Wang J, Zhang LP, Wu CY, Jin J,
Sang JR, Lu HY, Gong AH, Du FY and Peng WX: Aging alters histone H3
lysine 4 methylation in mouse germinal vesicle stage oocytes.
Reprod Fertil Dev. 27:419–426. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang L, Wang J, Pan Y, Jin J, Sang J,
Huang P and Shao G: Expression of histone H3 lysine 4 methylation
and its demethylases in the developing mouse testis. Cell Tissue
Res. 358:875–883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Wan X, Wei Y, Liu X, Lai W, Zhang L,
Jin J, Wu C, Shao Q, Shao G and Lin Q: LSD1-mediated epigenetic
modification contributes to ovarian cancer cell migration and
invasion. Oncol Rep. 35:3586–3592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davis A, Tinker AV and Friedlander M:
‘Platinum resistant’ ovarian cancer: What is it, who to treat and
how to measure benefit. Gynecol Oncol. 133:624–631. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayakawa J, Ohmichi M, Kurachi H, Ikegami
H, Kimura A, Matsuoka T, Jikihara H, Mercola D and Murata Y:
Inhibition of extracellular signal-regulated protein kinase or
c-Jun N-terminal protein kinase cascade, differentially activated
by cisplatin, sensitizes human ovarian cancer cell line. J Biol
Chem. 274:31648–31654. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Persons DL, Yazlovitskaya EM, Cui W and
Pelling JC: Cisplatin-induced activation of mitogen-activated
protein kinases in ovarian carcinoma cells: Inhibition of
extracellular signal-regulated kinase activity increases
sensitivity to cisplatin. Clin Cancer Res. 5:1007–1014.
1999.PubMed/NCBI
|
|
26
|
Ding J, Zhang ZM, Xia Y, Liao GQ, Pan Y,
Liu S, Zhang Y and Yan ZS: LSD1-mediated epigenetic modification
contributes to proliferation and metastasis of colon cancer. Br J
Cancer. 109:994–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang GG, Allis CD and Chi P: Chromatin
remodeling and cancer, Part I: Covalent histone modifications.
Trends Mol Med. 13:363–372. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li M, Lewis B, Capuco AV, Laucirica R and
Furth PA: WAP-TAg transgenic mice and the study of dysregulated
cell survival, proliferation, and mutation during breast
carcinogenesis. Oncogene. 19:1010–1019. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El Mansouri FE, Nebbaki SS, Kapoor M, Afif
H, Martel-Pelletier J, Pelletier JP, Benderdour M and Fahmi H:
Lysine-specific demethylase 1-mediated demethylation of histone H3
lysine 9 contributes to interleukin 1β-induced microsomal
prostaglandin E synthase 1 expression in human osteoarthritic
chondrocytes. Arthritis Res Ther. 16:R1132014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vergara D, Merlot B, Lucot JP, Collinet P,
Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal
transition in ovarian cancer. Cancer Lett. 291:59–66. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin T, Ponn A, Hu X, Law BK and Lu J:
Requirement of the histone demethylase LSD1 in Snai1-mediated
transcriptional repression during epithelial-mesenchymal
transition. Oncogene. 29:4896–4904. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI,
Evers BM and Zhou BP: The SNAG domain of Snail1 functions as a
molecular hook for recruiting lysine-specific demethylase 1. EMBO
J. 29:1803–1816. 2010. View Article : Google Scholar : PubMed/NCBI
|
